-

Bayer’s SVP and Head of Corporate Affairs Ray Kerins to Host Full Day Workshop During TLF’s 22nd Anniversary Scholarship Program

LOS ANGELES & WHIPPANY, N.J.--(BUSINESS WIRE)--Life Science company Bayer will host a full day workshop during The LAGRANT Foundation (TLF)’s 22nd Anniversary Scholarship Program at its facility in New Jersey on Wednesday, May 20, 2020. The workshop will be led by Raymond (Ray) F. Kerins Jr., Bayer’s senior vice president, head of Corporate Affairs.

In his role, Kerins manages all communications, government relations, and philanthropy for the company. Previously, he was the vice president of external affairs and worldwide communications for pharmaceutical corporation Pfizer, where he oversaw internal and external communications for the company globally. Kerins is part of the host committee for TLF’s 22nd Anniversary Scholarship Program in 2020, which he was also part of during the 20th anniversary in 2018.

“This workshop with Bayer is an excellent addition to the 2020 scholarship program,” said TLF Chairman & CEO Mr. Kim L. Hunter. “I am looking forward to seeing what Ray and his team will have planned for what I’m positive will be an insightful and informative event.”

The event will include panel discussions and Q&A sessions with Bayer employees, talks led by Kerins, and a networking lunch. The workshop will round out TLF’s four-day scholarship program in which 50 ethnic minority students will receive $150,000 in scholarships and participate in career development and professional workshops with other marketing and advertising agencies in New York.

For more information on TLF, please visit www.lagrantfoundation.org.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.us.

About The LAGRANT Foundation (TLF)

Since its inception in 1998, The LAGRANT Foundation (TLF) has provided 576 scholarships and $2.57 million to continue its mission to increase the number of ethnic minorities in the fields of advertising, marketing and public relations. With the generous support of its major donors and supporters, TLF provides students with career & professional development workshops, scholarships, internships, entry-level positions and mentors to African American/Black, Alaska Native/Native American, Asian American/Pacific Islander and Hispanic/Latino undergraduate and graduate students.

Note to reporters and editors: “The” in The LAGRANT Foundation name is part of the Foundation’s legal name. Please do not drop the “The” or lowercase the “T.” When spelling “LAGRANT,” capitalize all letters. As an alternative, you can use the letters TLF in lieu of The LAGRANT Foundation.

Contacts

Camille Frigillana/Mr. Kim L. Hunter
323.469.8680, ext. 240/225
camillefrigillana@lagrant.com
kimhunter@lagrant.com

Bayer Media Contact:
Carolyn Nagle
(201) 419-0337
Carolyn.nagle@bayer.com

Bayer LogoBayer Logo

Bayer


Release Versions

Contacts

Camille Frigillana/Mr. Kim L. Hunter
323.469.8680, ext. 240/225
camillefrigillana@lagrant.com
kimhunter@lagrant.com

Bayer Media Contact:
Carolyn Nagle
(201) 419-0337
Carolyn.nagle@bayer.com

More News From Bayer

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in soybeans and specialty crops in the United States, making these biologicals economically viable witho...

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (...

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026) – found that 82% worry about their own and their families' wellbeing due...
Back to Newsroom